Literature DB >> 23317311

Prevascularized microtemplated fibrin scaffolds for cardiac tissue engineering applications.

Kassandra S Thomson1, F Steven Korte, Cecilia M Giachelli, Buddy D Ratner, Michael Regnier, Marta Scatena.   

Abstract

Myocardial infarction (MI) causes significant cell loss and damage to myocardium. Cell-based therapies for treatment of MI aim to remuscularize the resultant scar tissue, but the majority of transplanted cells do not survive or integrate with the host tissue. Scaffolds can improve cell retention following construct implantation, but often do little to enhance host-graft integration and/or show limited biodegradation. Fibrin is an ideal biomaterial for cardiac tissue engineering as it is a natural, biodegradable polymer that can induce neovascularization, promote cell attachment, and has tunable mechanical properties. Here we describe a novel, high-density microtemplated fibrin scaffold seeded with a tri-cell mixture of cardiomyocytes, endothelial cells (ECs), and fibroblasts to mimic native cardiac tissue in structure and cellular composition to improve cell retention and promote integration with the host tissue. Scaffolds were designed with uniform architecture of parallel 60 μm microchannels surrounded by an interconnected microporous network of 27-μm-diameter pores and mechanical stiffness comparable to native cardiac tissues (70-90kPa). Scaffold degradation was controlled with the addition of Factor XIII (FXIII) and/or protease inhibitor (aprotinin). Unmodified scaffolds had a fast degradation profile both in vitro (19.9%±3.9% stiffness retention after 10 days) and in vivo. Scaffolds treated with FXIII showed an intermediate degradation profile in vitro (45.8%±5.9%), while scaffolds treated with aprotinin or both FXIII and aprotinin showed significantly slowed degradation in vitro (60.9%±5.2% and 76.4%±7.6%, respectively, p<0.05). Acellular aprotinin scaffold myocardial implants showed decreased collagen deposition after 7 days. Unmodified and aprotinin implants could not be located by 14 days, while 2 of 8 FXIII implants were found, but were significantly degraded. Constructs supported seeded cell survival and organization in vitro, promoting EC-lined lumen structure formation in construct channels and colocalization of viable ECs and cardiomyocytes. In addition, constructs promoted extracellular matrix deposition by seeded cells, as shown by collagen staining within construct channels and by significant increases in construct stiffness over 10 days in vitro (209%±32%, p<0.05). The data suggest our fibrin scaffolds are ideally designed to promote graft cell survival and organization, thus improving chances of promoting construct integration with the host tissue upon implantation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23317311      PMCID: PMC3589898          DOI: 10.1089/ten.tea.2012.0286

Source DB:  PubMed          Journal:  Tissue Eng Part A        ISSN: 1937-3341            Impact factor:   3.845


  38 in total

1.  Neovascularization of immunoisolation membranes: the effect of membrane architecture and encapsulated tissue.

Authors:  J Brauker; L A Martinson; R S Hill; S K Young; V E Carr-Brendel; R C Johnson
Journal:  Transplant Proc       Date:  1992-12       Impact factor: 1.066

Review 2.  What does it take to make the perfect clot?

Authors:  Dougald M Monroe; Maureane Hoffman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-10-27       Impact factor: 8.311

3.  Engineering vascularized skeletal muscle tissue.

Authors:  Shulamit Levenberg; Jeroen Rouwkema; Mara Macdonald; Evan S Garfein; Daniel S Kohane; Diane C Darland; Robert Marini; Clemens A van Blitterswijk; Richard C Mulligan; Patricia A D'Amore; Robert Langer
Journal:  Nat Biotechnol       Date:  2005-06-19       Impact factor: 54.908

4.  Subunit B of factor XIII is present in bovine platelets.

Authors:  J Takagi; K Kasahara; F Sekiya; Y Inada; Y Saito
Journal:  Thromb Res       Date:  1988-06-15       Impact factor: 3.944

Review 5.  Factor XIII, clot structure, thrombosis.

Authors:  Zsuzsa Bagoly; Zsuzsa Koncz; Jolán Hársfalvi; László Muszbek
Journal:  Thromb Res       Date:  2011-12-24       Impact factor: 3.944

Review 6.  Aprotinin and preservation of myocardial function after ischemia-reperfusion injury.

Authors:  David A Bull; Jennifer Maurer
Journal:  Ann Thorac Surg       Date:  2003-02       Impact factor: 4.330

7.  Implantation of bone marrow mononuclear cells using injectable fibrin matrix enhances neovascularization in infarcted myocardium.

Authors:  Ju Hee Ryu; Il-Kwon Kim; Seung-Woo Cho; Myeong-Chan Cho; Kyung-Kuk Hwang; Hainan Piao; Shuguang Piao; Sang Hyun Lim; Yoo Sun Hong; Cha Yong Choi; Kyung Jong Yoo; Byung-Soo Kim
Journal:  Biomaterials       Date:  2005-01       Impact factor: 12.479

8.  Effects of fibrin on the angiogenesis in vitro of bovine endothelial cells in collagen gel.

Authors:  A Takei; Y Tashiro; Y Nakashima; K Sueishi
Journal:  In Vitro Cell Dev Biol Anim       Date:  1995-06       Impact factor: 2.416

9.  Neovascularization of synthetic membranes directed by membrane microarchitecture.

Authors:  J H Brauker; V E Carr-Brendel; L A Martinson; J Crudele; W D Johnston; R C Johnson
Journal:  J Biomed Mater Res       Date:  1995-12

10.  Fibrin glue alone and skeletal myoblasts in a fibrin scaffold preserve cardiac function after myocardial infarction.

Authors:  Karen L Christman; Hubert H Fok; Richard E Sievers; Qizhi Fang; Randall J Lee
Journal:  Tissue Eng       Date:  2004 Mar-Apr
View more
  21 in total

1.  Analyzing Structure and Function of Vascularization in Engineered Bone Tissue by Video-Rate Intravital Microscopy and 3D Image Processing.

Authors:  Yonggang Pang; Olga Tsigkou; Joel A Spencer; Charles P Lin; Craig Neville; Brian Grottkau
Journal:  Tissue Eng Part C Methods       Date:  2015-07-24       Impact factor: 3.056

Review 2.  Three-dimensional scaffold-free microtissues engineered for cardiac repair.

Authors:  Alejandra Patino-Guerrero; Jaimeson Veldhuizen; Wuqiang Zhu; Raymond Q Migrino; Mehdi Nikkhah
Journal:  J Mater Chem B       Date:  2020-07-29       Impact factor: 6.331

Review 3.  Engineered circulatory scaffolds for building cardiac tissue.

Authors:  Shixing Huang; Yang Yang; Qi Yang; Qiang Zhao; Xiaofeng Ye
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

4.  Scalable units for building cardiac tissue.

Authors:  Xiaofeng Ye; Liang Lu; Martin E Kolewe; Keith Hearon; Kristin M Fischer; Jonathan Coppeta; Lisa E Freed
Journal:  Adv Mater       Date:  2014-09-19       Impact factor: 30.849

5.  Aprotinin extends mechanical integrity time of cell-seeded fibrin sutures.

Authors:  Spencer T Coffin; Glenn R Gaudette
Journal:  J Biomed Mater Res A       Date:  2016-05-14       Impact factor: 4.396

Review 6.  Striated muscle function, regeneration, and repair.

Authors:  I Y Shadrin; A Khodabukus; N Bursac
Journal:  Cell Mol Life Sci       Date:  2016-06-06       Impact factor: 9.261

7.  Effects of polycaprolactone-based scaffolds on the blood-brain barrier and cerebral inflammation.

Authors:  Vincent Diong Weng Nga; Jing Lim; David Kim Seng Choy; Mya Aye Nyein; Jia Lu; Ning Chou; Tseng Tsai Yeo; Swee-Hin Teoh
Journal:  Tissue Eng Part A       Date:  2015-01-22       Impact factor: 3.845

Review 8.  3D biofabrication strategies for tissue engineering and regenerative medicine.

Authors:  Piyush Bajaj; Ryan M Schweller; Ali Khademhosseini; Jennifer L West; Rashid Bashir
Journal:  Annu Rev Biomed Eng       Date:  2014-05-29       Impact factor: 9.590

9.  Stromal Cells in Dense Collagen Promote Cardiomyocyte and Microvascular Patterning in Engineered Human Heart Tissue.

Authors:  Meredith A Roberts; Dominic Tran; Kareen L K Coulombe; Maria Razumova; Michael Regnier; Charles E Murry; Ying Zheng
Journal:  Tissue Eng Part A       Date:  2016-03-31       Impact factor: 3.845

10.  Multi-Material Tissue Engineering Scaffold with Hierarchical Pore Architecture.

Authors:  Kathy Ye Morgan; Demetra Sklaviadis; Zachary L Tochka; Kristin M Fischer; Keith Hearon; Thomas D Morgan; Robert Langer; Lisa E Freed
Journal:  Adv Funct Mater       Date:  2016-06-13       Impact factor: 18.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.